Expert consensus on use of SGLT2i and GLP-1RAs for CV risk reduction in T2DM
The Journal of the American College of Cardiology has published an expert consensus decision pathway (ECDP) on novel therapies for CV risk reduction in patients with T2DM .
Over the past years, several studies have shown that SGLT2i and GLP-1RAs reduce the risk of major adverse CV events (MACE). SGLT2i also reduce the risk of HF hospitalization and progression of diabetic kidney disease (DKD) [2-9]. The mechanisms of CV and renal benefits with these compounds remains uncertain, but appear to exceed their direct glucose-lowering effects [10,11]. Since CVD remains the leading cause of morbidity and mortality in T2DM, awareness of clinical evidence regarding CV benefits of SGLT2i and GLP1RAs is of importance to CV specialists. This ECDP provides guidance on initiation and monitoring of SGLT2i or GLP-1RAs with proven CV benefit in T2DM patients with ASCVD, HF, DKD or at high risk for ASCVD, with the goal of reducing CV risk.